Evigrade
DrugsCosmetic ingredientsCalculatorsInteractionsEvigrade SkinEvigrade Meds ↗
ConditionsJournalMethodologyPro for practitioners
ESRU

Pramipexole

AEMPS

Non-ergot dopamine D2/D3 receptor agonist

ATC code: N04BC05

Updated · Methodology

Indications

A

Parkinson's disease

First line

First-line in Parkinson's disease in patients under 65 to delay levodopa per 2021 and SEN 2024. In patients over 65, levodopa start is preferred. Starting dose 0.125 mg three times daily (immediate-release) or 0.375 mg once daily (extended-release), slowly titrated to 1.5–4.5 mg daily. Added to levodopa for motor fluctuations. CALM-PD showed pramipexole reduces dyskinesia risk by 50% in the first 5 years but causes more non-motor side effects.

Sources

  1. AEMPS: Ficha técnica de Pramipexol (2024)
  2. Neurology: Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee. (2021)
  3. JAMA: Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. (2000)
  4. BMC Neurol: Efficacy of pramipexole on quality of life in patients with Parkinson's disease: a systematic review and meta-analysis. (2022)

ICD-10: G20 · ICD-11: 8A00.0

B

Restless legs syndrome

Second line

Second-line for moderate-to-severe restless legs syndrome per 2024 and EFNS/ENS 2012. First-line is iron supplementation in ferritin deficiency (under 75 ng/mL) and α2δ ligands (gabapentin, pregabalin). Pramipexole 0.125–0.5 mg 2–3 hours before bed. Long-term use is linked to augmentation phenomenon – symptom worsening with daytime spread; when augmentation appears, switch the drug.

Sources

  1. AEMPS: Ficha técnica de Pramipexol (2024)
  2. Journal of Clinical Sleep Medicine: Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine clinical practice guideline (2025)
  3. Journal of Clinical Sleep Medicine: Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment (2025)
  4. Cochrane Database Syst Rev: Dopamine agonists for restless legs syndrome. (2011)

ICD-10: G25.81 · ICD-11: 7A80

Marketing claims without evidence base

The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.

F

Insomnia and sleep disorders

Not recommended

Pramipexole is a dopamine receptor agonist. It is prescribed for Parkinson's disease and for moderate-to-severe restless legs syndrome (RLS) ( 2018 guidelines and AEMPS Ficha Técnica). For unconfirmed mild RLS or stress-related muscle tension, pramipexole is not used: these indications are not in international guidelines. The drug has serious risks: pathological gambling, hypersexuality, compulsive eating and shopping ( warning, 2014), sudden sleep attacks with risk of falling asleep at the wheel, and augmentation on long-term RLS treatment (paradoxical worsening of symptoms). If pramipexole was prescribed for leg sensations or muscle relaxation outside confirmed RLS, consider seeking a second opinion and check serum ferritin (iron deficiency is a common cause of RLS).

Sources

  1. AEMPS: Ficha técnica de Pramipexol (2024)
  2. ESRS: European guideline for the diagnosis and treatment of insomnia (2023)

ICD-10: G47.0 · ICD-11: 7A00

How to read tiers A–F
  • AStrong evidence – first or second line in international guidelines
  • BRecommended in selected cases
  • CStudy data contradict each other
  • DBenefit not proven, no documented harm
  • FDocumented harm, or risk without benefit

Mechanism of action

A selective D2-family dopamine receptor agonist with preferential D3 affinity (5–7-fold over D2). Mimics dopamine action in nigrostriatal and mesolimbic pathways. Compared with ergot agonists (bromocriptine, pergolide), no risk of fibrotic complications (valvular heart disease, pulmonary fibrosis). Half-life 8–12 hours immediate-release; 22 hours extended-release.

Safety

Contraindications

  • Pramipexole hypersensitivity
  • Severe renal impairment without dose adjustment
  • Pregnancy and lactation
  • Age under 18

Serious adverse effects

  • Impulse-control disorders (pathological gambling, hypersexuality, binge eating, compulsive shopping) – FDA 2012 and EMA 2014 warning
  • Augmentation in restless legs syndrome
  • Sudden sleep attacks without warning while driving
  • Psychotic disorders
  • Dopamine dysregulation syndrome
  • Heart failure (with long-term high doses)

Common adverse effects

  • Nausea
  • Drowsiness and sudden sleep attacks
  • Dizziness
  • Orthostatic hypotension
  • Dyskinesias (in Parkinson's with concomitant levodopa)
  • Constipation
  • Hallucinations

Pregnancy: can you take Pramipexole?

Limited data. In pregnant Parkinson's patients, decisions are made with the neurologist.

Breastfeeding: can you take Pramipexole?

Suppresses lactation via prolactin inhibition. Not used during lactation.

Calculate RIDFull profile on NIH LactMed ↗

Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.

Practical notes

Common myths

Myth: «pramipexole is a modern, safe drug with no serious adverse effects.» Fact: in 2012 and in 2014 issued a warning about impulse-control disorders on dopamine agonists: pathological gambling, hypersexuality, binge eating, compulsive shopping. Frequency 13–17% in Parkinson's patients on pramipexole, reversible after discontinuation. Before start and every 3 months, ask the patient and family about these symptoms – the patient often does not link them to the drug.
Label mentions5 mentions

Verbatim lines from the interaction sections, in the language of the label

From this drug’s label

  • Majorantipsicóticosclass named in the label
    «Medicamentos antipsicóticos: Debe evitarse la administración concomitante de medicamentos antipsicóticos con pramipexol (ver sección 4.4), p. ej. si se puede esperar antagonismo .»

    AEMPS, section 4.5 · Open on CIMA

  • Moderatedepresores del SNCclass named in the label
    «Combinación con levodopa: Debido a posibles efectos aditivos, debe tenerse especial precaución cuando los pacientes estén tomando otros medicamentos sedantes o alcohol, en combinación con pramipexol…»

    AEMPS, section 4.5 · Open on CIMA

  • antipsychoticsclass named in the label
    «Dopamine Antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide…»

    FDA, section 7 · Open on DailyMed

  • Metoclopramide
    «Dopamine Antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide…»

    FDA, section 7 · Open on DailyMed

  • Selegiline
    «Unión a proteínas plasmáticas: La unión de pramipexol a las proteínas plasmáticas es muy baja (< 20%), al igual que el metabolismo en humanos. Por consiguiente, son improbables las interacciones con…»

    AEMPS, section 4.5 · Open on CIMA

Check interaction with another drug

Opens the checker prefilled with this drug. Pick the second one from your regimen.

Open checker

Summary of a multi-drug list →

Medicine list: everything you take in one place →

Frequently asked

What is Pramipexole used for?

Pramipexole is evaluated for the following indications with varying evidence strength: Parkinson's disease (evidence tier A), Restless legs syndrome (evidence tier B), Insomnia and sleep disorders (evidence tier F). See the full indication matrix with dosing and citations above on this page.

What are the side effects of Pramipexole?

Common side effects of Pramipexole (≥ 1 in 100): Nausea, Drowsiness and sudden sleep attacks, Dizziness, Orthostatic hypotension, Dyskinesias (in Parkinson's with concomitant levodopa), Constipation. See the Safety section for uncommon and serious reactions.

Is Pramipexole safe during pregnancy?

Limited data. In pregnant Parkinson's patients, decisions are made with the neurologist.

Is Pramipexole compatible with breastfeeding?

Suppresses lactation via prolactin inhibition. Not used during lactation.

Who should not take Pramipexole?

Pramipexole is contraindicated in: Pramipexole hypersensitivity; Severe renal impairment without dose adjustment; Pregnancy and lactation; Age under 18. Full list in the Safety section.

Official sources

Direct links to regulator labels. Open in a new tab.

Other drugs in this group

Bromocriptine, Cabergoline, Levodopa + Carbidopa + Entacapone, Rasagiline, Ropinirole, Selegiline